1380089-81-5
Chemical Structure
CPI-0610 carboxylic acid
- CAS No.: 1380089-81-5
- Formula:C20H15ClN2O3
- Molecular Weight:366.80
IUPAC Name: (S)-2-(6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetic acid
InChIKey: DBLBPRFLLZXMOW-INIZCTEOSA-N
SMILES: O=C(O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC=CC=C3C4=C1ON=C4C
Biological Activity: CPI-0610 carboxylic acid is a novel small-molecule bromodomain and extraterminal protein inhibitor for the treatment of multiple myeloma. CPI-0610 carboxylic acid binds to the N-terminal bromodomains of BRD2, BRD3, BRD4, and BRDT, as well as the BRD9 bromodomain. CPI-0610 carboxylic acid can serve as a target protein ligand for the synthesis of PROTAC. CPI-0610 carboxylic acid can be used for research on multiple myeloma, acute myeloid leukemia, and lung and cervical cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CPI-0610 carboxylic acid | CPI-0610 carboxylic acid is a novel small-molecule bromodomain and extraterminal protein inhibitor for the treatment of multiple myeloma. CPI-0610 carboxylic acid binds to the N-terminal bromodomains of BRD2, BRD3, BRD4, and BRDT, as well as the BRD9 bromodomain. CPI-0610 carboxylic acid can serve as a target protein ligand for the synthesis of PROTAC. CPI-0610 carboxylic acid can be used for research on multiple myeloma, acute myeloid leukemia, and lung and cervical cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Siu KT, et al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 2017 Aug;31(8):1760-1769. [Content Brief]
- [2]. Wellaway CR, et al. Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype. Journal of Medicinal Chemistry. 2020 Aug 3;63(17):9020-44.
- [3]. Wilson B, et al. Developing small molecule inhibitors of bromodomain-histone interactions (Doctoral dissertation, University of Oxford).
